BioCardia, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
BioCardia, Inc. (BCDA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-03-29
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $0.00.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $1.50M.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.90M.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- BioCardia, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $1.50M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 | |||
| 2021-12-31 | $1.90M 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | $0.00 derived: sum of 3 quarters · filed 2021-03-30 | $1.50M 10-K · filed 2021-03-30 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $1.50M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $1.50M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $1.50M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |